Royalty Pharma plc
RPRX
Rang in aandelen
#867
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Aandeelprijs
$62.21
Marktkapitalisatie
$27.70B
Verandering (1 dag)
3.22%
Verandering (1 jaar)
69.83%
Land
US
Handel Royalty Pharma plc (RPRX)
Categorie
Healthcare
Winst voor Royalty Pharma plc (RPRX)
Winst in Jun 2026 TTM: $1.35B
Volgens de meest recente financiële verslagen van Royalty Pharma plc bedraagt de huidige winst van het bedrijf $1.35B. In 2024 behaalde het bedrijf een winst van $1.33B, een daling ten opzichte van de winst van 2023, die $1.70B bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Royalty Pharma plc van 2015 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $1.35B | 1.94% |
| 2025 | $1.32B | -0.50% |
| 2024 | $1.33B | -21.72% |
| 2023 | $1.70B | 638.96% |
| 2022 | $230.06M | -81.46% |
| 2021 | $1.24B | -27.07% |
| 2020 | $1.70B | -30.85% |
| 2019 | $2.46B | 62.16% |
| 2018 | $1.52B | 13.00% |
| 2017 | $1.34B | 76.29% |
| 2016 | $761.90M | 0.42% |
| 2015 | $758.71M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $26.37M | -98.05% |
US
|
|
| $1.21B | -10.73% |
HK
|
